Cortisol metabolic predictors of response to psychotherapy for symptoms of PTSD in survivors of the World Trade Center attacks on September 11, 2001

被引:81
作者
Yehuda, Rachel [1 ,2 ]
Bierer, Linda M. [1 ,2 ]
Sarapas, Casey [1 ,2 ]
Makotkine, Iouri [1 ,2 ]
Andrew, Ruth [3 ]
Seckl, Jonathan R. [3 ]
机构
[1] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY 10468 USA
[2] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA
[3] Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland
基金
英国惠康基金;
关键词
Posttraumatic stress disorder; Cortisol; Cortisol metabolites; Glucocorticoid metabolism; Biological markers; Psychotherapy; 5; alpha-Reductase; 5 alpha-Tetrahydrocortisol (5 alpha-THF); POSTTRAUMATIC-STRESS-DISORDER; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; COGNITIVE-BEHAVIORAL THERAPY; HOLOCAUST SURVIVORS; PLASMA-CORTISOL; SEXUAL ABUSE; HPA-AXIS; COMBAT; DEPRESSION; VETERANS;
D O I
10.1016/j.psyneuen.2009.03.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A proportion of subjects with symptoms of posttraumatic stress disorder (PTSD) are unresponsive to specialized psychotherapy, but a biological basis for this has not been described. To observe whether differences in cortisol or its metabolites predict or correlate with response to therapy for PTSD symptoms, cortisol and its metabolites were measured from urine samples at pre-treatment, at the conclusion of psychotherapy, and at 3-month follow-up. Methods: 28 survivors of the World Trade Center attacks on September 11, 2001 seeking psychological treatment for PTSD symptoms received four sessions of either exposure therapy or supportive counseling, followed by up to 10 sessions of prolonged exposure in a specialized PTSD treatment program at a private hospital serving the New York City metropolitan area. 24-h mean integrated cortisol excretion was assessed by radioimmunoassay (RIA); urinary free cortisol and metabolites cortisone, 5 alpha-tetrahydrocortisol (5 alpha-THF), 5 beta-tetrahydrocortisol, and tetrahydrocortisone were assessed by gas chromatography-mass spectrometry (GC-MS); and indices of enzyme activity for 5 alpha- and 5 beta-reductase and for the 11 beta-hydroxysteroid dehydrogenases were derived from the metabolite and glucocorticoid measures. Results: 5 alpha-Reductase activity was significantly tower at pre-treatment among non-responders, whereas there were no significant pre-treatment differences between responders and non-responders in any other hormone or metabolite level. In repeated measures analyses across the three time points, 5 alpha-reductase activity, as well as 5 alpha-THF and total glucocorticoids, significantly differed between responders and non-responders. For urinary cortisol measured by RIA, there was a significant group x time interaction indicating that, although not different at pre-treatment, urinary cortisol levels declined over time in the non-responder group, such that by follow-up, towered cortisol significantly distinguished non-responders from responders. Indices of 5 alpha-reductase activity, including 5 alpha-THF and total glucocorticoids, were significantly negatively correlated with avoidance symptom severity at pre-treatment. At follow-up, indices of 5 alpha-reductase activity were significantly negatively correlated with severity of all three PTSD symptom clusters and with total PTSD severity scores. Conclusion: Lower 5 alpha-reductase activity is associated with avoidance severity and predicts non-responsiveness to psychological treatment for PTSD symptomatology. Relatively diminished 5 alpha-reductase activity may mark a state of primary vulnerability, perhaps via attenuated peripheral catabolism of cortisol resulting in the suppression of hypothalamic-pituitary-ad renal axis responsiveness. Lower cortisol levels appear later in the progression to chronic, treatment-resistant PTSD. Published by Elsevier Ltd.
引用
收藏
页码:1304 / 1313
页数:10
相关论文
共 63 条
  • [11] Treatment of acute stress disorder - A randomized controlled trial
    Bryant, Richard A.
    Mastrodomenico, Julie
    Felmingham, Kim L.
    Hopwood, Sally
    Kenny, Lucy
    Kandris, Eva
    Cahill, Catherine
    Creamer, Mariz
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2008, 65 (06) : 659 - 667
  • [12] Predicting PTSD prospectively based on prior trauma history and immediate biological responses
    Delahanty, Douglas L.
    Nugent, Nicole R.
    [J]. PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER: A DECADE OF PROGRESS, 2006, 1071 : 27 - 40
  • [13] EDWARDS CR, 1998, LANCET, V2, P986
  • [14] A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder
    Ehlers, A
    Clark, DM
    Hackmann, A
    McManus, F
    Fennell, M
    Herbert, C
    Mayou, R
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (10) : 1024 - 1032
  • [15] The validation of a self-report measure of posttraumatic stress disorder: The Posttraumatic Diagnostic Scale
    Foa, EB
    Cashman, L
    Jaycox, L
    Perry, K
    [J]. PSYCHOLOGICAL ASSESSMENT, 1997, 9 (04) : 445 - 451
  • [16] FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405
  • [17] MMPI-2 as a predictor of change in PTSD symptom clusters: A further analysis of the Forbes et al. (2002) data set
    Forbes, D
    Creamer, M
    Allen, N
    McHugh, T
    Debenham, P
    Hopwood, M
    [J]. JOURNAL OF PERSONALITY ASSESSMENT, 2003, 81 (02) : 183 - 186
  • [18] MMPI-2 based subgroups of veterans with combat-related PTSD - Differential patterns of symptom change after treatment
    Forbes, D
    Creamer, M
    Allen, N
    Elliott, P
    McHugh, T
    Debenham, P
    Hopwood, M
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 2003, 191 (08) : 531 - 537
  • [19] The MMPI-2 as a predictor of symptom change following treatment for posttraumatic stress disorder
    Forbes, D
    Creamer, M
    Allen, N
    Elliott, P
    McHugh, T
    Debenham, P
    Hopwood, M
    [J]. JOURNAL OF PERSONALITY ASSESSMENT, 2002, 79 (02) : 321 - 336
  • [20] Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5α-reductase
    Frye, CA
    Walf, AA
    Rhodes, ME
    Hamey, JP
    [J]. BRAIN RESEARCH, 2004, 1004 (1-2) : 116 - 124